ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 81.46%.
Alto crecimiento de los beneficios
Los ingresos netos de la empresa lideran el sector. Sus ingresos anuales más recientes ascienden a 883.37M USD.
Cambio hacia las ganancias
El rendimiento de la empresa ha pasado a ser rentable. Sus ingresos netos anuales más recientes han sido de USD.
Valorada de forma justa
El PE más reciente de la empresa es 20.19, en un rango percentil medio de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 23.15M acciones, lo que supone un aumento del 0.25% con respecto al trimestre anterior.
En posesión de John Hussman
El inversor estrella John Hussman posee 49.41K acciones de este valor.